Should I buy or sell Astellas Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALPMY shares. View ALPMY analyst ratings or view top-rated stocks .

How have ALPMY shares performed in 2023?

Astellas Pharma's stock was trading at $15.16 at the start of the year. Since then, ALPMY stock has decreased by 19.0% and is now trading at $12.28. View the best growth stocks for 2023 here .

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest in October. As of October 31st, there was short interest totaling 48,000 shares, an increase of 1,197.3% from the October 15th total of 3,700 shares. Based on an average daily trading volume, of 792,600 shares, the days-to-cover ratio is presently 0.1 days. View Astellas Pharma's Short Interest .

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.17 by $0.18. The firm earned $2.71 billion during the quarter. Astellas Pharma had a net margin of 2.06% and a trailing twelve-month return on equity of 8.74%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.15 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 125.01%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ALPMY will have a dividend payout ratio of 18.29% next year. This indicates that the company will be able to sustain or increase its dividend.

When did Astellas Pharma's stock split?

Astellas Pharma's stock split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Astellas Pharma have any subsidiaries?

The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos. Read More

Astellas Pharma Stock Price, News & Analysis (OTCMKTS:ALPMY)

$12.28

+0.12 (+0.99%)

(As of 12/1/2023 ET)

Compare

Today's Range: $11.75
▼
$12.28
50-Day Range: $11.57
▼
$14.44
52-Week Range: $11.25
▼
$16.91

Volume: 191,640 shs
Average Volume: 324,764 shs
Market Capitalization: $22.22 billion

P/E Ratio: 102.34
Dividend Yield: 1.22%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Insider Trades SEC Filings Short Interest

Astellas Pharma MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: -0.53
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 22.39%
From $0.67 to $0.82 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Astellas Pharma.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of Astellas Pharma have been sold short.
Short Interest Ratio / Days to Cover
Astellas Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Astellas Pharma has recently increased by 3.75%, indicating that investor sentiment is decreasing.

1.7

Dividend Strength

Dividend Yield
Astellas Pharma pays a meaningful dividend of 1.26%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Astellas Pharma does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Astellas Pharma is 125.01%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 18.29% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALPMY.

1.4

News and Social Media Coverage

News Sentiment
Astellas Pharma has a news sentiment score of -0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Astellas Pharma this week, compared to 2 articles on an average week.
MarketBeat Follows
1 people have added Astellas Pharma to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Astellas Pharma insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.04% of the stock of Astellas Pharma is held by institutions.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Astellas Pharma are expected to grow by 22.39% in the coming year, from $0.67 to $0.82 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Astellas Pharma is 102.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of Astellas Pharma is 102.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.34.
Price to Earnings Growth Ratio
Astellas Pharma has a PEG Ratio of 0.80. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Astellas Pharma has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALPMY Stock News Headlines

December 1, 2023 | markets.businessinsider.com

Astellas : FDA Grants Priority Review For SBLA Of Padcev Combination For Bladder Cancer Treatment

November 30, 2023 | finance.yahoo.com

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 29, 2023 | finance.yahoo.com

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

November 27, 2023 | bizjournals.com

Propella Therapeutics, Pittsboro firm with 5 employees, sold for $175M

November 21, 2023 | seekingalpha.com

ALPMY Astellas Pharma Inc.

November 17, 2023 | markets.businessinsider.com

Pfizer, Astellas' XTANDI Gets FDA Approval For Nonmetastatic Castration-sensitive Prostate Cancer

November 16, 2023 | bizjournals.com

Pittsboro firm with 5 employees sold for $175M

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 16, 2023 | finance.yahoo.com

University of Tsukuba and Astellas Confirm a Strategic Partnership

November 15, 2023 | markets.businessinsider.com

Astellas Pharma To Buy Propella Therapeutics For About $175 Mln

November 15, 2023 | finance.yahoo.com

Astellas to Acquire Propella Therapeutics

November 15, 2023 | finance.yahoo.com

Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology

November 1, 2023 | reuters.com

Japan's Astellas says Q2 profit slid 94%, cuts annual forecast

November 1, 2023 | markets.businessinsider.com

Astellas Pharma H1 Profit Down; Cuts FY23 Profit View, Lifts Revenue Forecast

October 22, 2023 | finance.yahoo.com

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

October 19, 2023 | finance.yahoo.com

China Arrests Japanese Executive Despite Tokyo’s Appeals

October 15, 2023 | finance.yahoo.com

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

October 13, 2023 | markets.businessinsider.com

Astellas' Veoza Receives Positive CHMP Opinion For Treatment Of VMS Associated With Menopause

October 13, 2023 | finance.yahoo.com

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

October 11, 2023 | markets.businessinsider.com

Astellas Pharma, BioLabs And Mitsui Fudosan Collaborate To Enhance Life Science Ecosystems In Japan

September 22, 2023 | markets.businessinsider.com

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

September 20, 2023 | markets.businessinsider.com

What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?

September 20, 2023 | finance.yahoo.com

Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)

September 18, 2023 | finance.yahoo.com

Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize

September 18, 2023 | finance.yahoo.com

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

September 18, 2023 | finance.yahoo.com

Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society

See More Headlines

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/02/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ALPMY
CUSIP: N/A
CIK: 1446390
Web: www.astellas.com
Phone: (133) 244-3000
Fax: N/A
Employees: 14,484
Year Founded: 1923

Profitability

EPS (Most Recent Fiscal Year): $0.12
Trailing P/E Ratio: 102.34
Forward P/E Ratio: 18.33
P/E Growth: 0.8
Net Income: $742 million
Net Margins: 2.06%
Pretax Margin: 8.71%
Return on Equity: 8.74%
Return on Assets: 4.88%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 0.96
Quick Ratio: 1.13

Sales & Book Value

Annual Sales: $11.24 billion
Price / Sales: 1.98
Cash Flow: $1.37 per share
Price / Cash Flow: 8.95
Book Value: $6.25 per share
Price / Book: 1.96

Miscellaneous

Outstanding Shares: 1,809,660,000
Free Float: N/A
Market Cap: $22.22 billion
Optionable: Not Optionable
Beta: 0.50

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Naoki Okamura BSc (Age 61)
President, CEO & Director
Comp: $963.45k
Mr. Atsushi Kitamura
Chief Financial Officer
Nobue Yasuda
General Manager of Finance & Accounting Department
Mr. Yoshitsugu Shitaka Ph.D.
Chief Scientific Officer & Senior Managing Executive Officer
Ms. Catherine B. Levitt
General Counsel
Mr. Katsuyoshi Sugita (Age 56)
Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
Mr. Stig Ogata
Vice President of Corporate Communications
Ms. Collette Taylor (Age 60)
Senior Vice President of Human Resources
Ms. Tatjana Dragovic
Senior VP and Head of Ethics & Compliance
Mr. Nobuaki Tanaka
President of Japan Commercial & Senior Corporate Executive

Key Competitors

View All Competitors

ALPMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALPMY shares.
View ALPMY analyst ratings or view top-rated stocks.
How have ALPMY shares performed in 2023?: Astellas Pharma's stock was trading at $15.16 at the start of the year. Since then, ALPMY stock has decreased by 19.0% and is now trading at $12.28.
View the best growth stocks for 2023 here.
Are investors shorting Astellas Pharma?: Astellas Pharma saw a increase in short interest in October. As of October 31st, there was short interest totaling 48,000 shares, an increase of 1,197.3% from the October 15th total of 3,700 shares. Based on an average daily trading volume, of 792,600 shares, the days-to-cover ratio is presently 0.1 days.
View Astellas Pharma's Short Interest.
How were Astellas Pharma's earnings last quarter?: Astellas Pharma Inc. (OTCMKTS:ALPMY) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.17 by $0.18. The firm earned $2.71 billion during the quarter. Astellas Pharma had a net margin of 2.06% and a trailing twelve-month return on equity of 8.74%.

Is Astellas Pharma a good dividend stock?: Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.15 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 125.01%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ALPMY will have a dividend payout ratio of 18.29% next year. This indicates that the company will be able to sustain or increase its dividend.
When did Astellas Pharma's stock split?: Astellas Pharma's stock split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.
How do I buy shares of Astellas Pharma?: Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Astellas Pharma have any subsidiaries?: The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More

This page (OTCMKTS:ALPMY) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Astellas Pharma Stock Price, News & Analysis (OTCMKTS:ALPMY)

Astellas Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Astellas Pharma Stock (OTCMKTS:ALPMY)

ALPMY Stock Price History

ALPMY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

ALPMY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™